Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.780 +0.220 (+6.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,657,523
Open 3.590
Bid (Size) 3.730 (2)
Ask (Size) 3.770 (4)
Prev. Close 3.560
Today's Range 3.550 - 3.790
52wk Range 2.900 - 11.16
Shares Outstanding 85,076,300
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-46.8%
-46.8%
1 Month
+9.6%
+9.6%
3 Month
-36.5%
-36.5%
6 Month
-30.7%
-30.7%
1 Year
-40.8%
-40.8%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
From Pomerantz LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Class Action Filed Against Altimmune, Inc. (ALT) - October 6, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Altimmune, Inc. (ALT) - October 6, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
Via NewMediaWire
Topics Fraud Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
From Pomerantz LLP
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
From Pomerantz LLP
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
From The Rosen Law Firm PA
Via GlobeNewswire
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Via TheNewswire.com
Topics Fraud Lawsuit
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?
Yes, Altimmune, Inc. - Common Stock is publicly traded.
What exchange does Altimmune, Inc. - Common Stock trade on?
Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Altimmune, Inc. - Common Stock?
The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 3.780
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 09/05/25 04:00 PM ET
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 321.59M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 322M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.